Latest Breaking News On - சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம் - Page 9 : comparemela.com

email article SAN ANTONIO An online tool, which incorporates clinicopathological data and the results of the 21-gene recurrent score, was able to estimate risk of distant recurrence (DR) and adjuvant chemotherapy benefit in certain patients with breast cancer, a researcher reported. The RSClin tool integrates the recurrence score (RS) with tumor grade, tumor size, and age using a patient-specific meta-analysis that included 10,004 women with hormone receptor-positive, HER2-negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 trial, or with chemotherapy in the TAILORx trial, explained Joseph Sparano, MD, of Montefiore Medical Center and the Albert Einstein College of Medicine in New York City, at the San Antonio Breast Cancer Symposium virtual meeting. The study was simultaneously published in the

New yorkUnited statesColumbia universitySan antonioJoseph sparanoMontefiore medical centerAlbert einstein college of medicineAlbert einstein collegeNew york citySan antonio breast cancer symposiumGenomic dataInform shared decisionClin oncolபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்கொலம்பியா பல்கலைக்கழகம்